Today's guest is Scott Bradley, VP of AI and Innovation at Novartis. As the eighth largest pharmaceutical company in the world by revenue, Novartis' medicines reach millions of people worldwide. Their focus on the discovery and development of novel, breakthrough treatments sees them reimagining not just the delivery of said treatments, but the practice of medicine at large. Scott joins Emerj Editorial Director Matthew DeMello to examine how artificial intelligence is transforming trial design, operations, and patient engagement — while also reshaping industry trust and accountability. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the 'AI in Business' podcast!
